Co - Mentor
The neurovascular unit and Alzheimer’s disease.
Drs. Lawrence and Murphy have a long standing collaboration to better understand the dynamic nature of the blood brain barrier (BBB) under normal and pathological conditions. Previously, the Lawrence/Murphy labs have investigated how the serine protease tissue‐type plasminogen activator (tPA) regulates BBB permeability through neuroserpin (a member of the serine protease inhibitor [serpin] family) and how this signaling pathway significantly affects seizure progression in mice (PMID: 26273685). Current efforts are focused on the role that the protease inhibitor, PAI-1 (plasminogen activation inhibitor) plays in vascular remodeling observed in mouse models of Alzheimer’s disease and how this remodeling impacts neuronal and cognitive function. Experimental approaches include tissue clearing, confocal microscopy, behavioral analysis and synaptic physiology.